Furthermore, we identified enhanced low-grade systemic inflammation as a relevant factor that may contribute to diminished HDL function independent of HDL-C and apoA-I levels specifically in the context of T2DM and MetS. The gene discussed is APOA1; the disease is type 2 diabetes mellitus.